CD8A and neoplasm: Compared to HD-IL2, BEMPEG preferentially binds to the low-to-moderate affinity heterodimeric IL2βγ (CD122/132) receptors predominately expressed on NK and CD8 T cells, compared to the high-affinity trimeric IL2αR predominately expressed on immunosuppressive T regulatory cells (Tregs), and stimulates an anti-tumor immune response through the clonal expansion of NK and CD4 and CD8 T cells.